Volume 6, Issue 4 (11-2016)                   Iran J Ped Hematol Oncol 2016, 6(4): 244-248 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tahmasebi L, Haghpanah S, Rezaei N, Karimi M. Red Cell Enzymopathies in Patients with Hemolytic Anemia in Southern Iran: Case Series . Iran J Ped Hematol Oncol 2016; 6 (4) :244-248
URL: http://ijpho.ssu.ac.ir/article-1-273-en.html
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract:   (3643 Views)

Abstract

Background:

Hereditary red cell enzyme disorders are a group of Non-immune/Spherocytic Hemolytic Anemia, although these disorders are rare and they have not public health problems, the detection of these defects could help to physician in treatment and differential diagnosis. This study evaluated 5 enzymopathies in patients with Hereditary Non –immune/Spherocytic Hemolytic Anemia (HNSHA) during one year.

Materials and Methods:

This cross-sectional study, evaluated 5 erythrocyte enzymes in 22 patients (mean age of 10 ± 9.3) with Hereditary Non-immune/ Spherocytic Hemolytic Anemia in Southern Iran from Jan 2014- Feb 2015. Evaluated erythrocyte enzymes consisted of pyruvate kinase (PK), G6PD, Catalase, Glutathion Proxidase( GP) and Glutathion Reductase( GR), all of these enzymes checked by quantitative assay except G6PD that evaluated by qualitative activity assay. The clinical and para clinical data were gathered from patient’s documents. Results: Results showed that 2 patients were PK deficient (9.1 %), 4 patients were G6PD deficient (18.2%), 1patient was GP deficient (4.5%), 1 patient was Catalase deficient (4.5%) and there is no patient with GR deficiency.

Conclusion:

This study showed that enzymopathies should be into consideration in patients with non-immune hemolytic anemia, if other common causes of hemolysis such as hemoglobinopathies and membranopathies have been excluded. 

Full-Text [PDF 177 kb]   (1373 Downloads)    
Type of Study: Research | Subject: Heart
Received: 2016/01/13 | Accepted: 2016/04/10 | Published: 2016/10/29

References
1. Arya R, Layton DM, Bellingham AJ. Hereditary red cell enzymopathies. Blood Rev 1995; 9:165–75. [Article]
2. van Wijk R, van Solinge WW. Disorders of red cells resulting from enzyme abnormalities. Williams Hematology. Kaushansky KJ, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT. (eds). New York: McGraw-Hill, 2010: 647–74. [Article]
3. Jacobasch G, Rapoport SM. Hemolytic anemias due to erythrocyte enzyme deficiencies. Mol Aspects Med 1996;17: 143–70. [Article]
4. Beutler E. Red Cell Metabolism. A Manual of Biochemical Methods. 3rd Ed. Orlando, FL, Grune & Stratton, 1984. [Article]
5. Lewis SM, Bain BJ, Bates I. Dacie and Lewis Practical Haematology. 10th Ed. London: Curchill Livingstone, 2006: 205-237. [Article]
6. Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol 2005; 130:11–25. [Article]
7. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371:64–74. [Article]
8. Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol 2014; 164: 469–80. [Article]
9. Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood 2000; 95: 3585–8. [Article]
10. van Wijk R, Huizinga EG, Prins I, Kors A, Rijksen G, Bierings M, et al. Distinct phenotypic expression of two de novo missense mutations affecting the dimer interface of glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis 2004; 32(1):112-7. [Article]
11. Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Pyruvate kinase deficiency: the genotype -phenotype association. Blood Rev 2007; 21(4):217-31. [Article]
12. Van Wijk R, Huizinga EG, Van Wesel ACW, Van Oirschot BA, Hadders MA, van Solinge WW. Fifteen novel mutations in PKLR associated with pyruvate kinase (PK) deficiency: structural implications of amino acid substitutions in PK. Hum Mutat 2009; 30(3):446-53. [Article]
13. Kugler W, Lakomek M. Glucose-6-phosphate isomerase deficiency. Bailliere’s best practice & research Clinical haematology 2000; 13(1):89-101. [Article]
14. Orosz F, Oláh J, Ovádi J. Triosephosphate isomerase deficiency: New insights into an enigmatic disease. Biochim Biophys Acta 2009; 1792(12):1168-74. [Article]
15. Zanella A, Bianchi P, Fermo E, Valentini G. Hereditary pyrimidine 5’-nucleotidase deficiency: from genetics to clinical manifestations. Br J Haematol 2006; 133(2):113-23. [Article]
16. Njålsson R, Ristoff E, Carlsson K, Winkler A, Larsson A, Norgren S. Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency. Hum Genet 2005; 116(5):384-9. [Article]
17. Beutler E. PGK deficiency. Br J Haematol 2007; 136(1):3-11. 18. Usanga EA, Ameen R. Glucose-6-phosphate dehydrogenase deficiency in Kuwait, Syria, Egypt, Iran, Jordan, and lebanan. Hum Hered 2000; 50:158-61. [Article]
18. Lou MF. Redox regulation in lens. Prog Retin Eye Res 2003; 22:657-682. 20- Beutler E. Red cell enzyme defects as nondiseases and as diseases. Blood 1979; 54:1–7. [Article]

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Pediatric Hematology and Oncology

Designed & Developed by : Yektaweb